Indication
Cutaneous T-Cell Lymphoma Refractory
2 clinical trials
2 products
Product
LB1901Clinical trial
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)Status: Active (not recruiting), Estimated PCD: 2025-05-01
Product
Mogamulizumab